Michael Morris
Pulmonary Disease · Fort Sam Houston, TXNPI 1861482416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,040 of the $77,858 with a category attached, or 86.1%. 15 manufacturers reported payments, led by Johnson & Johnson at 51.8% of the total. Reporting peaked in 2019 at $46,505 and has fallen 99.5% since, to $232 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $794.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$40K
- GSK$35K
- Viiv Healthcare Company$600
- Intuitive Surgical$258
- Boehringer Ingelheim$229
- Chiesi USA, Inc.$189
- plus $1K from 9 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$67,04086%
- Travel & lodging$7,55110%
- Food & beverage$2,7974%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 49 | $40,364 |
| GSK | 33 | $35,100 |
| Viiv Healthcare Company | 1 | $600 |
| Intuitive Surgical | 1 | $258 |
| Boehringer Ingelheim | 2 | $229 |
| Chiesi USA, Inc. | 2 | $189 |
| Exthera Medical Corporation | 1 | $180 |
| Mylan Specialty L.p. | 2 | $179 |
| Monaghan Medical Corporation | 1 | $150 |
| Actelion Pharmaceuticals US, Inc. | 1 | $150 |
| AstraZeneca | 1 | $125 |
| Novo Nordisk | 1 | $117 |
| Circassia Inc. | 1 | $103 |
| 4dmedical USA Inc | 1 | $94 |
| Grifols Shared Services North America, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$39,975
- ANORO$17,328
- TRELEGY ELLIPTA$16,597
- Da Vinci Surgical System$258
- Aerobika$150
- UPTRAVI$150
- FASENRA$125
- OFEV$125
- Norditropin$117
- Yupelri$104
- NIOX VERO$103
How this compares
$77,858 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Fort Sam Houston
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.